Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia

New England Journal of Medicine

Volumn 339, Issue 26, 1998, Pages 1869-1874

  McColl, Kenneth ^a   Murray, Lilian ^a   El Omar, Emad ^a   Dickson, Anthea ^a   El Nujumi, Adil ^a   Wirz, Angela ^a   Kelman, Andrew ^a   Penny, Christine ^b   Knill Jones, Robin ^c   Hilditch, Thomas ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b VICTORIA INFIRMARY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CARBON 14; IMMUNOGLOBULIN G ANTIBODY; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE; UREA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DYSPEPSIA; FEMALE; GASTROINTESTINAL ENDOSCOPY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DRUG THERAPY, COMBINATION; DYSPEPSIA; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LOGISTIC MODELS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; TETRACYCLINE;

EID: 0032564695     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199812243392601     Document Type: Article

References (29)

1. Jones RH, Lydeard SE, Hobbs FDR, et al. Dyspepsia in England and Scotland. Gut 1990;31:401-5.
2. Bernersen B, Johnson R, Straume B, Burhol PG, Jenssen TG, Stakkevold PA. Towards a true prevalence of peptic ulcer: the Sorreisa gastrointestinal disorder study. Gut 1990;31:989-92.
3. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102:1259-68.
4. Nyrén O, Lindberg G, Lindstrom E, Marke L-A, Seensalu R. Economic costs of functional dyspepsia. Pharmacoeconomics 1992;1:312-24.
5. Johannessen T, Petersen H, Kleveland PM, et al. The predictive value of history in dyspepsia. Scand J Gastroenterol 1990;25:689-97.
6. Jebbink HJA, Smout AJPM, Van Berg-Henegouwen GP. Pathophysiology and treatment of functional dyspepsia. Scand J Gastroenterol Suppl 1993;200:8-14.
7. Talley NJ. Functional dyspepsia - should treatment be targeted on disturbed physiology? Aliment Pharmacol Ther 1995;9:107-15.
8. Mearin F, Cucala M, Azpiroz F, Malagelada J-R. The origin of symptoms on the brain-gut axis in functional dyspepsia. Gastroenterology 1991; 101:999-1006.
9. O'Riordan T, Mathai E, Tobin E, et al. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut 1990;31: 999-1002.
10. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobocter pylori. Lancet 1988;2:1437-42.
11. Hentschel E, Brandstätter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazolc on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N EngI J Med 1993;328:308-12.
12. Rauws EAJ, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990;335:1233-5.
13. Armstrong D. Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol Suppl 1996;215:38-47.
14. Talley NJ. Helicobacter pylori and non-ulcer dyspepsia. Scand J Gastroenterol Suppl 1996;220:19-22.
15. Talley NJ, Hunt RH. What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology 1997;113:Suppl: S67-S77.
16. Management of dyspepsia: report of a working party. Lancet 1988;1: 576-9.
17. El-Omar EM, Banerjee S, Wirz A, McColl KEL. The Glasgow Dyspepsia Severity Score - a tool for the global measurement of dyspepsia. Eur J Gastroenterol Hepatol 1996;8:967-71.
18. Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 1993;306:1440-4.
19. McColl KEL, el-Nujumi A, Murray L, et al. The Helicobacter pylori breath test: a surrogate marker for peptic ulcer in dyspeptic patients. Gut 1997;40:302-6.
20. Xiang Z, Bugnoli M, Ponzetto A, et al. Detection in an enzyme im-munoassay of an immune response to a recombinant fragment of the 128 kilodalton protein (CagA) of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1993;12:739-45.
21. Megraud F. Advantages and disadvantages of current diagnostic tests for the detection of Helicobacter pylori. Scand J Gastroenterol Suppl 1996; 215:57-62.
22. Gilvarry J, Buckley MJM, Beattie S, Hamilton H, O'Morain CA. Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scand J Gastroenterol 1997;32:535-40.
23. El-Omar EM, Penman ID, Ardill JES, Chittajallu RS, Howie C, McColl KEL. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995;109: 681-91.
24. Gillen D, el-Omar EM, Wirz AA, Ardill JES, McColl KEL. The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects. Gastroenterology 1998;114:50-7.
25. Cover TL, Glupczynski Y, Lage AP, et al. Serologic detection of infection with cagA+ Helicobacter pylori strains. J Clin Microbiol 1995;33: 1496-500.
26. Matysiak-Budnik T, Poniewierka E, Gasciniak G, Jelen M, Knapik Z. A 5-year follow-up study of chronic gastritis patients. Ir J Med Sci 1992; 161:Suppl 10:37. abstract.
27. Reilly TG, Ayres RCS, Poxon V, Walt RP. Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Aliment Pharmacol Ther 1995;9:483-90.
28. Phull PS, Halliday D, Price AB, Jaqua MR. Absence of dyspeptic symptoms as a test for Helicobacter pylori eradication. BMJ 1996;312:349-50.
29. McColl KEL, el-Nujumi A, Murray LS, et al. Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer. Gut 1998;42:618-22.